
|Articles|July 15, 2004
Verteporfin-maker QLT to merge with Atrix
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
2
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
3
Development of maculopathy associated with systemic medications
4
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
5

















































.png)


